METHODS	In an 8-week , randomized , double-blind , placebo-controlled , parallel group crossover trial , 17 cannabis-nave patients with MS were assessed at baseline and at the end of the cannabis and placebo phases of the trial ( each of 3 weeks ) by means of Symptom Checklist-90 Revised , Self-rating Anxiety Scale , Multiple Sclerosis Functional Composite ( of which 1 dimension is the Paced Auditory Serial Additional Test that was used to evaluate cognition ) , Visual Analogue Scale on health-related quality of life , Multiple Sclerosis Impact Scale-29 , and Fatigue Severity Scale .\